Immuneering (IMRX) News Today → Forget the “Magnificent 7” Tech Companies, Buy This AI Stock Instead (From Banyan Hill Publishing) (Ad) Free IMRX Stock Alerts $1.55 -0.02 (-1.27%) (As of 01:44 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 12, 2024 | americanbankingnews.comNeedham & Company LLC Reiterates "Buy" Rating for Immuneering (NASDAQ:IMRX)May 8, 2024 | markets.businessinsider.comBuy Rating Maintained for Immuneering Amid Promising Clinical Pipeline DevelopmentsMay 7, 2024 | globenewswire.comImmuneering Reports First Quarter 2024 Financial Results and Provides Business UpdatesMay 7, 2024 | finance.yahoo.comWe Think Immuneering (NASDAQ:IMRX) Needs To Drive Business Growth CarefullyMay 6, 2024 | globenewswire.comImmuneering Recognizes Melanoma Awareness MonthMay 2, 2024 | markets.businessinsider.comBuy Rating Affirmed: Immuneering’s Lead Asset IMM-1-104 Shows Promise Despite Market SkepticismApril 17, 2024 | msn.comImmuneering (IMRX) Price Target Decreased by 11.43% to 13.55April 15, 2024 | marketbeat.comImmuneering Co. (NASDAQ:IMRX) Sees Significant Growth in Short InterestImmuneering Co. (NASDAQ:IMRX - Get Free Report) was the target of a large increase in short interest in March. As of March 31st, there was short interest totalling 2,880,000 shares, an increase of 10.3% from the March 15th total of 2,610,000 shares. Based on an average daily trading volume, of 595,100 shares, the short-interest ratio is presently 4.8 days. Approximately 14.0% of the shares of the stock are short sold.April 12, 2024 | marketbeat.comNeedham & Company LLC Reiterates Buy Rating for Immuneering (NASDAQ:IMRX)Needham & Company LLC reiterated a "buy" rating and set a $15.00 price objective on shares of Immuneering in a research note on Friday.April 11, 2024 | investing.comImmuneering advances pancreatic cancer treatment trialApril 9, 2024 | finanznachrichten.deImmuneering Corporation: IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer ModelsApril 9, 2024 | globenewswire.comIMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer ModelsApril 9, 2024 | marketbeat.comImmuneering Co. (NASDAQ:IMRX) Given Consensus Rating of "Moderate Buy" by BrokeragesShares of Immuneering Co. (NASDAQ:IMRX - Get Free Report) have earned a consensus rating of "Moderate Buy" from the eight brokerages that are currently covering the company, MarketBeat reports. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy ratApril 5, 2024 | insidertrades.comCormorant Asset Management, Lp Sells 400,000 Shares of Immuneering Co. (NASDAQ:IMRX) StockApril 3, 2024 | globenewswire.comImmuneering to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceApril 2, 2024 | marketbeat.comMizuho Trims Immuneering (NASDAQ:IMRX) Target Price to $8.00Mizuho decreased their price objective on shares of Immuneering from $20.00 to $8.00 and set a "buy" rating for the company in a research report on Tuesday.March 29, 2024 | markets.businessinsider.comBuy Rating Affirmed for Immuneering on Solid Trial Progress and Insider ConfidenceMarch 27, 2024 | globenewswire.comImmuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS MutationsMarch 26, 2024 | insidertrades.com3 Stocks Insiders Are Buying That Analysts LoveMarch 26, 2024 | insidertrades.comImmuneering Co. (NASDAQ:IMRX) Insider Harold Eugene Brakewood Buys 3,900 SharesMarch 26, 2024 | insidertrades.comInsider Buying: Immuneering Co. (NASDAQ:IMRX) Director Acquires 25,000 Shares of StockMarch 25, 2024 | marketbeat.comImmuneering Co. (NASDAQ:IMRX) Insider Acquires $10,023.00 in StockImmuneering Co. (NASDAQ:IMRX - Get Free Report) insider Harold Eugene Brakewood bought 3,900 shares of the company's stock in a transaction dated Friday, March 22nd. The stock was bought at an average price of $2.57 per share, for a total transaction of $10,023.00. Following the acquisition, the insider now directly owns 3,900 shares of the company's stock, valued at $10,023. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.March 22, 2024 | insidertrades.comInsider Buying: Immuneering Co. (NASDAQ:IMRX) Insider Acquires 3,818 Shares of StockMarch 21, 2024 | investing.comImmuneering CEO acquires $55.3k in company stockMarch 21, 2024 | marketbeat.comLeah R. Neufeld Buys 3,818 Shares of Immuneering Co. (NASDAQ:IMRX) StockImmuneering Co. (NASDAQ:IMRX - Get Free Report) insider Leah R. Neufeld acquired 3,818 shares of the company's stock in a transaction on Wednesday, March 20th. The stock was acquired at an average price of $2.88 per share, with a total value of $10,995.84. Following the acquisition, the insider now owns 10,029 shares in the company, valued at approximately $28,883.52. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website.March 21, 2024 | finance.yahoo.comImmuneering Director Acquires 7.5% More StockMarch 20, 2024 | insidertrades.comImmuneering Co. (NASDAQ:IMRX) CEO Purchases $55,400.00 in StockMarch 19, 2024 | marketbeat.comInsider Buying: Immuneering Co. (NASDAQ:IMRX) CEO Acquires 20,000 Shares of StockImmuneering Co. (NASDAQ:IMRX - Get Free Report) CEO Benjamin J. Zeskind purchased 20,000 shares of the business's stock in a transaction dated Tuesday, March 19th. The stock was bought at an average cost of $2.77 per share, for a total transaction of $55,400.00. Following the purchase, the chief executive officer now owns 2,281,852 shares in the company, valued at $6,320,730.04. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.March 19, 2024 | insidertrades.comCormorant Asset Management, Lp Sells 509,091 Shares of Immuneering Co. (NASDAQ:IMRX) StockMarch 18, 2024 | msn.comImmuneering stock rebounds 34% following last week's selloffMarch 18, 2024 | marketbeat.comInsider Selling: Immuneering Co. (NASDAQ:IMRX) Major Shareholder Sells 509,091 Shares of StockImmuneering Co. (NASDAQ:IMRX - Get Free Report) major shareholder Cormorant Asset Management, Lp sold 509,091 shares of the company's stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $3.72, for a total transaction of $1,893,818.52. Following the completion of the sale, the insider now directly owns 3,695,273 shares of the company's stock, valued at $13,746,415.56. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Large shareholders that own 10% or more of a company's stock are required to disclose their transactions with the SEC.March 18, 2024 | marketbeat.comImmuneering (NASDAQ:IMRX) Price Target Cut to $16.00Chardan Capital reduced their price target on shares of Immuneering from $21.00 to $16.00 and set a "buy" rating on the stock in a research report on Friday.March 18, 2024 | marketbeat.comImmuneering's (IMRX) "Neutral" Rating Reiterated at GuggenheimGuggenheim reiterated a "neutral" rating on shares of Immuneering in a research report on Thursday.March 18, 2024 | benzinga.comWhy Science Applications International Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Monday's Mid-Day SessionMarch 18, 2024 | msn.comCanopy Growth, Outlook Therapeutics, Immuneering among healthcare moversMarch 15, 2024 | msn.comU.S. shares lower at close of trade; Dow Jones Industrial Average down 0.49%March 15, 2024 | markets.businessinsider.comImmuneering: Hold Rating Amidst Potential and Uncertainties in Drug EfficacyMarch 15, 2024 | markets.businessinsider.comCancer Treatment Focused Immuneering Faces Analyst Downgrades, Who Cite Underwhelming Solid Tumor Trial DataMarch 15, 2024 | marketbeat.comImmuneering Co. (NASDAQ:IMRX) Receives Consensus Recommendation of "Moderate Buy" from AnalystsShares of Immuneering Co. (NASDAQ:IMRX - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the seven ratings firms that are covering the stock, MarketBeat.com reports. Three analysts have rated the stock with a hold rating and four have issued a buy rating on the coMarch 15, 2024 | marketbeat.comNeedham & Company LLC Cuts Immuneering (NASDAQ:IMRX) Price Target to $15.00Needham & Company LLC decreased their price objective on Immuneering from $20.00 to $15.00 and set a "buy" rating on the stock in a research note on Friday.March 15, 2024 | marketbeat.comImmuneering (NASDAQ:IMRX) Lowered to Market Perform at TD CowenTD Cowen cut Immuneering from an "outperform" rating to a "market perform" rating in a research report on Friday.March 14, 2024 | benzinga.comWhy Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionMarch 14, 2024 | msn.comWhat's Going On With Cancer-Focused Immuneering Stock On Thursday?March 14, 2024 | marketbeat.comTrading was temporarily halted for "IMRX" at 11:03 AM with a stated reason of "LULD pause." Trading set to resume at 11:03 AM. March 14, 2024 | marketbeat.comTrading was temporarily halted for "IMRX" at 09:03 AM with a stated reason of "LULD pause." Trading set to resume at 09:03 AM. March 14, 2024 | markets.businessinsider.comImmuneering IMM-1-104 Trial In RAS-Mutant Solid Tumors Shows Positive Results; Stock UpMarch 14, 2024 | globenewswire.comImmuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid TumorsMarch 13, 2024 | finanznachrichten.deImmuneering Corporation: Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid TumorsMarch 12, 2024 | finance.yahoo.comImmuneering Appoints Thomas J. Schall, Ph.D. to its Board of DirectorsMarch 12, 2024 | globenewswire.comImmuneering Appoints Thomas J. Schall, Ph.D. Get Immuneering News Delivered to You Automatically Sign up to receive the latest news and ratings for IMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Forget the “Magnificent 7” Tech Companies, Buy This AI Stock Instead (Ad)The AI boom continues to snowball with no signs of slowing... Google CEO, Sundar Pichai, made waves during a recent call with analysts, reminding them that the search engine company has been “AI first” since 2016. Get the full story here. IMRX Media Mentions By Week IMRX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMRX News Sentiment▼-0.220.55▲Average Medical News Sentiment IMRX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMRX Articles This Week▼32▲IMRX Articles Average Week Get Immuneering News Delivered to You Automatically Sign up to receive the latest news and ratings for IMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: AADI News CLNN News RMTI News BOLT News NXTC News RVPH News OCUP News HCWB News BLRX News GANX News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IMRX) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportBiden to Drop BOMBSHELL June 13th?Paradigm PressRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldElon to Transform U.S. Economy? Porter & CompanyCharles Payne Demystifies OptionsUnstoppable ProsperityThe most important AI company you've never heard ofManward PressThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyWATCH: The Truth About InflationBirch Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immuneering Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
